Iopamidol

Generic Name: Iopamidol

Brand Names: Isovue 200, Isovue 250, Isovue 300, Isovue 370, Isovue-M, Isovue-M 200

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₂I_₃N_₃O_₈

CAS Number: 60166-93-0

Unique Ingredient Identifier: JR13W81H44

Background: Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

Indication: 本品用于腰、胸肌颈段脊髓造影，脑血管造影，周围动脉造影剂静脉造影；也用于心血管、冠状动脉、尿路、关节等的造影剂CT增强。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

Phase 2

Recruiting

Conditions: Pancreatic Neoplasm
Duodenal Neoplasm

Interventions: Drug: Bupivacaine
Drug: Liposomal Bupivacaine
Drug: Hydromorphone
Drug: Iopamidol
Other: Medical Chart Review
Other: Questionnaire Administration
Procedure: Ultrasound Imaging
Drug: Thoracic Epidural Analgesia
Procedure: X-Ray Imaging

First Posted Date: 2024-05-13

Last Posted Date: 2024-05-13

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 78

Registration Number: NCT06411795

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA

Not Applicable

Conditions: Contrast Media Adverse Reaction

Interventions: Drug: Iopamidol

First Posted Date: 2022-08-05

Last Posted Date: 2022-08-05

Lead Sponsor: Chongqing Emergency Medical Center

Target Recruit Count: 500

Registration Number: NCT05489055

Locations: 🇨🇳
Chongqing Emergency Mediacl Centre, Chongqing, Chonqing, China

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

Not Applicable

Completed

Conditions: Malignant Solid Neoplasm

Interventions: Procedure: Advanced Magnetic Resonance Imaging
Procedure: Conventional Magnetic Resonance Imaging
Drug: Gadolinium-Chelate
Drug: Iopamidol

First Posted Date: 2021-05-03

Last Posted Date: 2024-11-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04870645

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer
HER2-negative Breast Cancer
ER Positive Breast Cancer
PR-Positive Breast Cancer

Interventions: Drug: Infigratinib
Drug: Tamoxifen
Drug: Omnipaque 350
Drug: Iopamidol
Diagnostic Test: Computed tomography (CT)

First Posted Date: 2020-08-07

Last Posted Date: 2023-06-01

Lead Sponsor: Jennifer Lee Caswell-Jin

Target Recruit Count: 4

Registration Number: NCT04504331

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Study With Oral Isovue in Abdominopelvic CT

Completed

Conditions: Patients Requiring Abdominopelvic CT With Oral Administration of Contrast

First Posted Date: 2020-07-01

Last Posted Date: 2023-02-08

Lead Sponsor: Bracco Diagnostics, Inc

Target Recruit Count: 218

Registration Number: NCT04453059

Locations: 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

Phase 4

Completed

Conditions: Percutaneous Coronary Intervention

Interventions: Drug: Iopamidol
Drug: adenosine
Device: Navvus® Catheter
Device: CVi® Contrast Delivery System

First Posted Date: 2018-06-15

Last Posted Date: 2024-07-05

Lead Sponsor: Duke University

Target Recruit Count: 201

Registration Number: NCT03557385

Locations: 🇺🇸
Long Beach VA, Long Beach, California, United States
🇺🇸
Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸
Durham VA, Durham, North Carolina, United States

and more 2 locations

Optimization of Contrast Agent Dose in CT With Lean Body Weight

Phase 4

Completed

Conditions: Contrast Agent With Lean Body Weight

Interventions: Drug: Iopamidol

First Posted Date: 2017-12-28

Last Posted Date: 2019-05-06

Lead Sponsor: IRCCS Policlinico S. Donato

Target Recruit Count: 274

Registration Number: NCT03384979

Locations: 🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers

Early Phase 1

Completed

Conditions: Metastatic Urothelial Carcinoma
Metastatic Renal Cell Carcinoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: Isovue-M 200

First Posted Date: 2017-03-06

Last Posted Date: 2022-04-11

Lead Sponsor: Duke University

Target Recruit Count: 10

Registration Number: NCT03071328

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Customized Contrast Media Dose Clinical Trial

Not Applicable

Terminated

Conditions: CT of the Abdomen and Pelvis With Contrast Material

Interventions: Drug: Iopamidol
Device: Mydose

First Posted Date: 2015-05-05

Last Posted Date: 2020-06-16

Lead Sponsor: Duke University

Target Recruit Count: 166

Registration Number: NCT02433665

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)

Phase 3

Completed

Conditions: Coronary Computed Tomographic Angiography

Interventions: Drug: Isovue 370
Drug: Visipaque 320

First Posted Date: 2014-06-24

Last Posted Date: 2014-08-15

Lead Sponsor: Duke University

Target Recruit Count: 35

Registration Number: NCT02171247

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy